About 30% of patients with acute myeloid leukemia (AML) harbor mutations in the gene encoding receptor-type tyrosine-protein kinase FLT3 in the form of internal tandem duplication (ITD) or mutations in the tyrosine kinase domain.
Researchers from Epics Therapeutics SA presented preclinical data for EP-102, a novel small-molecule inhibitor of N6-adenosine-methyltransferase catalytic subunit (METTL3), being developed for the treatment of cancer.
Chimeric antigen receptor (CAR) therapies targeted against CD19 have been widely used for the treatment of B-cell malignancies. However, the down-regulation of CD19 can lead to relapse, and autologous CAR T therapies have limitations that need to be addressed.
Researchers from Hibercell Inc. recently presented preclinical data for HC-7366, a first-in-class direct activator of GCN2 (general control nonderepressible 2) currently in phase I development for the treatment of solid tumors (NCT05121948).
HST-1021 is a novel mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) allosteric inhibitor identified using the Smart Allostery Platform, and is being developed for the potential treatment of tumors.
Nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) plays a central role in cancer metabolism as well as in metabolism in healthy tissues. Remedy Plan Therapeutics Inc. has presented data on the first hyperbolic Nampt inhibitor – RPT-1G – for the potential treatment of acute myeloid leukemia (AML).
Autologous chimeric antigen receptor (CAR) T-cell therapy has been one of the most recent successes in cancer treatment, but limitations, such as manufacturing, costs or antigen escape in therapies directed against only one target that leads to resistance, highlight the need for new approaches. Classical natural killer T (NKT) cells engineered to express CARs constitute a novel type of allogeneic therapy that does not require T-cell receptor (TCR) gene editing, thus avoiding graft-vs.-host disease (GVHD).
MYB is a transcription factor essential for cell proliferation and differentiation, and is regarded as a target for cancer therapy because it is overexpressed in many different tumor types such as adenoid cystic carcinoma (ACC), acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia, among others.
Researchers have developed a novel chronic lymphocytic leukemia (CLL) murine model that expresses human BCL2 in B cells under the TCL1 promoter control, named TBC.
It is known that CD19-directed CAR T-cell therapy is useful in the treatment of large B-cell lymphoma, but about 60% of patients relapse after treatment, and about 30% of these are CD19-negative patients with poor survival. Sana Biotechnology Inc. is developing a hypoimmune CD22-directed CAR T-cell therapy, named SC-262, for the potential treatment of large B-cell lymphoma.
